➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Dow
Colorcon
Mallinckrodt
McKinsey
Johnson and Johnson

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

ULTANE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Ultane patents expire, and when can generic versions of Ultane launch?

Ultane is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in ULTANE is sevoflurane. There are five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the sevoflurane profile page.

US ANDA Litigation and Generic Entry Outlook for Ultane

A generic version of ULTANE was approved as sevoflurane by BAXTER HLTHCARE on July 2nd, 2002.

  Start Trial

Drug patent expirations by year for ULTANE
Drug Prices for ULTANE

See drug prices for ULTANE

Recent Clinical Trials for ULTANE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Emory UniversityPhase 4
Stony Brook UniversityPhase 4
Rundo International Pharmaceutical Research & Development Co.,Ltd.Phase 4

See all ULTANE clinical trials

Pharmacology for ULTANE
Drug ClassGeneral Anesthetic
Physiological EffectGeneral Anesthesia
Paragraph IV (Patent) Challenges for ULTANE
Tradename Dosage Ingredient NDA Submissiondate
ULTANE LIQUID;INHALATION sevoflurane 020478

US Patents and Regulatory Information for ULTANE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie ULTANE sevoflurane LIQUID;INHALATION 020478-001 Jun 7, 1995 AN RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ULTANE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie ULTANE sevoflurane LIQUID;INHALATION 020478-001 Jun 7, 1995   Start Trial   Start Trial
Abbvie ULTANE sevoflurane LIQUID;INHALATION 020478-001 Jun 7, 1995   Start Trial   Start Trial
Abbvie ULTANE sevoflurane LIQUID;INHALATION 020478-001 Jun 7, 1995   Start Trial   Start Trial
Abbvie ULTANE sevoflurane LIQUID;INHALATION 020478-001 Jun 7, 1995   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Merck
McKesson
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.